Literature DB >> 9212909

Morpholino antisense oligomers: design, preparation, and properties.

J Summerton1, D Weller.   

Abstract

Antisense promised major advances in treating a broad range of intractable diseases, but in recent years progress has been stymied by technical problems, most notably inadequate specificity, ineffective delivery into the proper subcellular compartment, and unpredictable activity within cells. Herein is an overview of the design, preparation, and properties of Morpholino oligos, a novel antisense structural type that solves the sequence specificity problem and provides high and predictable activity in cells. Morpholino oligos also exhibit little or no nonantisense activity, afford good water solubility, are immune to nucleases, and are designed to have low production costs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212909     DOI: 10.1089/oli.1.1997.7.187

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  273 in total

Review 1.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes.

Authors:  Julian Schubert; Aleksandra Siekierska; Mélanie Langlois; Patrick May; Clément Huneau; Felicitas Becker; Hiltrud Muhle; Arvid Suls; Johannes R Lemke; Carolien G F de Kovel; Holger Thiele; Kathryn Konrad; Amit Kawalia; Mohammad R Toliat; Thomas Sander; Franz Rüschendorf; Almuth Caliebe; Inga Nagel; Bernard Kohl; Angela Kecskés; Maxime Jacmin; Katia Hardies; Sarah Weckhuysen; Erik Riesch; Thomas Dorn; Eva H Brilstra; Stephanie Baulac; Rikke S Møller; Helle Hjalgrim; Bobby P C Koeleman; Karin Jurkat-Rott; Frank Lehman-Horn; Jared C Roach; Gustavo Glusman; Leroy Hood; David J Galas; Benoit Martin; Peter A M de Witte; Saskia Biskup; Peter De Jonghe; Ingo Helbig; Rudi Balling; Peter Nürnberg; Alexander D Crawford; Camila V Esguerra; Yvonne G Weber; Holger Lerche
Journal:  Nat Genet       Date:  2014-11-02       Impact factor: 38.330

3.  Functional characterization of the dimer linkage structure RNA of Moloney murine sarcoma virus.

Authors:  H Ly; D P Nierlich; J C Olsen; A H Kaplan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Cyclin D and cdk4 are required for normal development beyond the blastula stage in sea urchin embryos.

Authors:  Jennifer C Moore; Jan L Sumerel; Bradley J Schnackenberg; Jason A Nichols; Athula Wikramanayake; Gary M Wessel; William F Marzluff
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

5.  Production of maternal-zygotic mutant zebrafish by germ-line replacement.

Authors:  Brian Ciruna; Gilbert Weidinger; Holger Knaut; Bernard Thisse; Christine Thisse; Erez Raz; Alexander F Schier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-23       Impact factor: 11.205

6.  Use of target protector morpholinos to analyze the physiological roles of specific miRNA-mRNA pairs in vivo.

Authors:  Alison A Staton; Antonio J Giraldez
Journal:  Nat Protoc       Date:  2011-12-01       Impact factor: 13.491

7.  Cyclic caged morpholinos: conformationally gated probes of embryonic gene function.

Authors:  Sayumi Yamazoe; Ilya A Shestopalov; Elayne Provost; Steven D Leach; James K Chen
Journal:  Angew Chem Int Ed Engl       Date:  2012-06-11       Impact factor: 15.336

8.  Analysis of circulating non-coding RNAs in a non-invasive and cost-effective manner.

Authors:  Yu-Min Wang; Michael Patrick Trinh; Yongzan Zheng; Kaizhu Guo; Luis A Jimenez; Wenwan Zhong
Journal:  Trends Analyt Chem       Date:  2019-07-05       Impact factor: 12.296

9.  Combinatorial control of gene function with wavelength-selective caged morpholinos.

Authors:  Sankha Pattanayak; Luis Angel Vázquez-Maldonado; Alexander Deiters; James K Chen
Journal:  Methods Enzymol       Date:  2019-04-25       Impact factor: 1.600

Review 10.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.